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Abstract
This study evaluated the relationships between compliance with oral hypoglycemic agents and health care/
short-term disability costs in a large manufacturing company. The retrospective analysis used an observational
cohort drawn from active employees of Ford Motor Company. The study population consisted of 4978 indi-
viduals who were continuously eligible for 3 years (between 2001–2007) and who received a prescription for an
oral hypoglycemic agent during that time. Medical, pharmacy, and short-term disability claims data were
obtained from the University of Michigan Health Management Research Center data warehouse. Pharmacy
claims/refill data were used to calculate the proportion of days covered (PDC); an individual was classified as
compliant if his/her PDC was ‡ 80%. Model covariates included age, sex, work type, and Charlson comorbidity
scores. The impact of compliance on disability and health care costs was measured by comparing the costs of the
compliant with those of the noncompliant during a 1-year follow-up. Among these employees, compliant
patients had lower medical, higher pharmacy, and lower short-term disability costs than did the noncompliant.
After adjusting for demographics and comorbidity, noncompliance was associated with statistically higher
short-term disability costs ($1840 vs. $1161, P< 0.0001), longer short-term disability duration, and an increase in
short-term disability incidence (21.5% of the noncompliant had a claim compared to 16.0% of the compliant,
P < 0.0001). These results suggest that medication compliance may be important in curtailing the rise of health
care/disability costs in the workplace. Employers concerned with the total costs associated with diabetes should
not overlook the impact of compliance on short-term disability. (Population Health Management 2014;17:35-41)
Introduction
Diabetes represents a significant financial burden toAmerican society in general and to US employers in
particular. Estimates from 2007 suggested that direct and in-
direct costs associated with diabetes exceeded $174 billion
annually.1 Numerous researchers have examined and quan-
tified the high medical and pharmacy costs associated with
diabetes1–3; similarly, studies on the productivity costs related
to the disease have shown that, on average, employees with
diabetes are more likely to be disabled,4 have more disability
claims,5 experience longer duration of disability,5 and report
lower productivity while at work6 than individuals without
diabetes. Although the data are contradictory, many re-
searchers also report that employees with diabetes miss more
days from work.4,7–11
The magnitude of this financial impact is especially so-
bering to employers who provide benefits such as medical
insurance, paid sick time, and disability to their employees.5
To date, efforts to mitigate the costs associated with diabetes
through disease management programs and/or interven-
tions targeted toward prevention of diabetes have produced
mixed results.3,12 Strategies specifically targeted to increase
compliance with hypoglycemic medications may be useful in
controlling or reducing costs associated with diabetes, al-
though noncompliance with such medication regimens is
high.13
For those patients with diabetes, compliance with hypo-
glycemic medications is often critical to achieve clinical
goals and to avoid serious medical complications of the
disease.14–17 Not only is compliance with hypoglycemic
medications related to health outcomes, but studies have
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shown a relationship between medication compliance and
total health care costs. In most examples, increased compli-
ance was associated with decreased medical expenditures
with an attendant increase in pharmacy spend, which often
results in modest savings in total health care costs.18–20
However, less is known about the impact of such com-
pliance on indirect costs such as short-term disability.
Recent reports have indicated that high adherence to oral
hypoglycemic agents is associated with fewer short-term
disability days,17 as well as fewer absent days,21 in an em-
ployer population. Another study found that increased ad-
herence to insulin or to oral hypoglycemic agents was a
significant predictor of improved job performance in the
workplace.22
Employers interested in containing disability and health
care costs need more guidance on the relationships between
medication compliance and indirect costs, such as those re-
lated to short-term disability. Toward this end, the present
study examines the impact of compliance with oral hypo-
glycemic agents on the medical, pharmacy, and short-term
disability costs among active employees of Ford Motor
Company. Given the composition and characteristics of this
employee population, the study results should be particu-
larly relevant to those concerned with the impact of medi-
cation compliance on the direct and indirect costs associated
with diabetes in the labor force.
Methods
This study was a retrospective analysis using an obser-
vational cohort comprised of employees of Ford Motor
Company. Ford is a multinational automaker primarily in-
volved with the production of cars, trucks, and commercial
vehicles. The data source for this analysis was the University
of Michigan Health Management Research Center (UM-
HMRC) database of medical and pharmacy claims and dis-
ability records. The study sample was restricted to active
full-time employees who were continuously eligible for
medical and pharmacy benefits for a 3-year time span from
January 1, 2001 through December 31, 2007; in those cases in
which an individual’s eligibility spanned a longer time pe-
riod, the most recent 3-year period was used in the analysis.
Other inclusion requirements were a prescription for an oral
hypoglycemic agent within the 3-year time span and a
minimum 30-day supply of that hypoglycemic agent. Oral
hypoglycemic agents were defined as those from the fol-
lowing drug classes: metformin, sulfonylureas, thiazolidi-
nones, meglitinides, and combinations thereof. Those
individuals with a prescription for insulin and/or any in-
jectable antidiabetic medications were excluded from the
study population because it is difficult to measure compli-
ance with injectable antidiabetic drugs using claims data
alone; furthermore, the outcomes and costs associated with
those individuals taking insulin plus an oral agent could
confound the results arising from those taking oral agents
alone. After application of these criteria, 4978 individuals
were chosen for the analysis.
Pharmacy claims were used to identify active employees
within a large manufacturing company who met the inclu-
sion criteria. Medical claims data were not used to identify or
verify participants with a diabetes diagnosis. The resulting
study sample included treatment-naı¨ve and treatment-
experienced patients, a population that is reflective of real-
world employer experience. Corresponding demographic
data such as sex, age, and job type (hourly vs. salaried) were
collected from the UM-HMRC database, but ethnicity data
were not available. Charlson comorbidity scores also were
calculated for individuals involved in the study using the
International Classification of Diseases, Ninth Revision codes in
their medical claims data. The Charlson comorbidity score/
index is an indicator that estimates the risk of death for an
individual based on the presence of diagnoses of specific
illnesses or chronic conditions in that individual’s medical
records.
For the purposes of this study, compliance was defined as
the proportion of days covered (PDC). Prescription drug
claims and refill data were used to determine the PDC; the
PDC was calculated as the number of days with drugs on
hand divided by 365.23,24 An individual was classified as
compliant if his or her PDC was ‡ 0.80.
The primary outcomes for this study were medical,
pharmacy, and short-term disability costs, all of which were
calculated for a 1-year follow-up. The 1-year follow-up (or
‘‘Year 1’’ in Tables 1–3) refers to the year immediately fol-
lowing the first occurrence of a drug fill for the oral hypo-
glycemic agent and does not refer to a calendar year; in
other words: Y1 = (date of first fill) + 365 days. Medical costs
included expenses related to outpatient services, emergency
room visits, and hospitalizations. Pharmacy costs were
those paid amounts for all drugs (not just those for the oral
hypoglycemic agent(s) in question). Both the pharmacy
paid amounts and the medical paid amounts were those
costs paid by the employer, exclusive of co-pays and de-
ductibles paid by the employee. Medical costs and phar-
macy costs were summed to provide the total health care
costs. Short-term disability costs were obtained from Ford
Motor Company records and were based on employee
salary, employee job type (hourly or salaried), and, if sala-
ried, employee job classification (general salaried or man-
agement). In general, Ford hourly employees on short-term
disability received approximately 60% of base pay, and
general salaried employees received 100% for 3 months and
then 63% for up to 9 additional months; in comparison,
management received 100% of base salary for 6 months and
then approximately 63% for up to 6 additional months. In
order to assess the impact of compliance on short-term
disability further (and to help mitigate the effects of benefit
design on related disability costs), the duration of short-
term disability absence also was calculated as weeks per
follow-up year (Year 1).
Multiple linear regression (general linear model in SAS)
was used to examine the association between medication
compliance and medical, pharmacy, and short-term dis-
ability costs. The appropriate statistical tests (Pearson chi-
square for categorical variables and t test for continuous
variables) were used to compare baseline demographic
factors and outcome relationships between compliant and
noncompliant populations. Cost estimates were adjusted
for the effects of sex (male or female), job type (hourly or
salaried), age (continuous), and Charlson comorbidity score
(continuous). Least squares means were computed and
compared using the PDIFF option. All statistical procedures
were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC).
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Results
Table 1 summarizes the demographic and compliance
characteristics of the study population. The participants were
largely male and predominantly hourly waged, reflective of
the manufacturing nature of Ford’s general work environ-
ment. Fifty-seven percent of the study population had a PDC
‡ 0.80.
Initial comparisons of demographics and costs between
the compliant and the noncompliant are shown in Table 2;
note that the means reported in Table 2 are unadjusted.
When compared to those individuals who are noncompliant
with their treatment regimen, compliant employees were
older and more likely to be male. The compliant also had
higher Charlson scores than the noncompliant. In the year
immediately following the first recorded pharmacy fill, the
compliant had lower mean medical costs than the non-
compliant. However, compliant individuals had higher
mean pharmacy costs in Year 1 than the noncompliant and
higher mean pharmacy costs for diabetes drugs alone. When
mean pharmacy and medical costs were combined to pro-
vide mean annual total health care costs, the compliant in-
dividuals were more costly overall than were the
noncompliant because of the much higher drug costs asso-
ciated with the compliant population. Short-term disability
costs for those compliant with their medications were much
lower than for those who were not compliant. The mean
duration of short-term disability absence also was shorter for
the compliant as compared to the noncompliant.
After controlling for age, sex, Charlson score, and job type,
compliance was significantly associated with medical costs,
pharmacy costs, and short-term disability costs (Table 3).
Individuals who were compliant with their oral hypoglyce-
mic agents had lower mean medical costs and higher mean
total pharmacy costs than the noncompliant. Not surpris-
ingly, the compliant also had higher mean pharmacy costs
for hypoglycemic agents alone. The combination of lower
mean medical costs and much higher mean pharmacy costs
meant that the average total health care cost for the com-
pliant group was slightly higher than that for the non-
compliant group. Finally, short-term disability costs were
negatively associated with increasing treatment compliance:
compliant individuals had much lower mean annual short-
term disability costs than did the noncompliant. When only
those individuals with a short-term disability claim were
included in the model, the compliant still had lower mean
annual disability costs than did the noncompliant.
Differences in short-term disability between the compliant
and the noncompliant were not restricted to cost alone. As
might be predicted, the mean duration of short-term dis-
ability absence was significantly shorter for the compliant
than for the noncompliant (Table 3). Table 4 compares the
percentage of those individuals in the compliant group with
a short-term disability claim to the analogous percentage of
those in the noncompliant group with a claim. During the
year in question, fewer individuals in the compliant group
filed a short-term disability claim than did the individuals in
the noncompliant group. The difference was statistically
significant.
Discussion
Claims data from Ford Motor Company revealed that
those patients with diabetes who were compliant with oral
hypoglemic agents had lower mean medical costs, higher
mean pharmacy costs, lower short-term disability costs, and
fewer weeks of short-term disability absence than did the
noncompliant, after controlling for demographics and co-
morbidities. The differences in short-term disability were
statistically significant and striking: not only did the com-
pliant have lower mean disability costs ($1161 vs. $1840 for
the noncompliant), they also reported a lower number of
disability claims, percentage-wise, than did the non-
compliant (16% of the compliant group filed a short-term
disability claim vs. 21.5% of the noncompliant).
All too often, medication compliance studies focus pri-
marily on health care costs and may not adequately address
indirect costs such as absence and short-term disability. As a
result, analyses that do not include the impact of compliance
on indirect costs may underestimate the severity and scope
of the noncompliance problem. Employers in particular need
more information on the complicated relationships between
patient compliance with antidiabetic regimens and outcomes
such as medical and disability costs, especially as the overall
impact of diabetes on the workforce continues to increase.
This study adds to the growing literature on diabetes costs
from the perspective of the employer5 by analyzing the fi-
nancial liability of diabetes on an employee population and
evaluating the effect of medication compliance on those
costs. These results are particularly relevant to US em-
ployers, given that the study population consisted of active
employees; it is also noteworthy that these employees were a
mixture of treatment-naı¨ve and treatment-experienced pa-
tients, representative of the diverse disease states and treat-
ment regimens present in a typical US workforce.
Although rates of short-term disability in the US work-
force are fairly low (generally 5–10 claims per 100 employees
per year), their workplace consequences are not.25 The bur-
den on employers is significant; in addition to the monetary
costs associated with employees’ short-term disability
claims, other costs (including those associated with replace-
ment wages and reduced productivity) may be equally im-
portant. Contrary to popular perception, most short-term
disability is not related to injury but rather to disease;
Table 1. Demographic and Compliance
Characteristics of the Study Population
Number Percentage
n 4978
Age categories
18–34 136 2.7
35–44 473 9.5
45–54 1911 38.4
55–64 2442 49.1
65+ 16 0.32
Mean age in years ( – S.D.) 53.0 (– 7.47)
Male sex 4242 85.2
Job categories
Hourly 3934 79.0
Salaried 1044 21.0
Mean Charlson score (– S.D.) 2.11 (– 1.86)
Mean adherence (– S.D.) 0.727 (– 0.308)
S.D., standard deviation.
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according to recent data from Unum, injury accounts for
only 11% of short-term disability claims.26 Employers inter-
ested in the total costs of employee health must be aware of
the nuances and importance of short-term disability on
overall health care expenditures.
In general, the results of the present study are consistent
with the findings of other research on the relationship be-
tween compliance with hypoglycemic medications and
health care expenditures. For example, in a study of adher-
ence among insured working-aged individuals diagnosed
with diabetes, Hepke reported that the adherent had higher
pharmacy costs, lower medical costs, and fewer emergency
room visits and inpatient admissions than did the non-
adherent.27 Using employer insurance data, Encinosa ob-
served a similar cost and utilization pattern among patients
adherent to an oral hypoglycemic regimen, where the higher
drug spend by the adherent group was associated with
lower rates of health care utilization.20 Sokol analyzed the
medical/pharmacy claims of a large manufacturing em-
ployer and determined that the lower medical cost incurred
by patients adherent to their hypoglycemic medications
more than compensated for their higher pharmacy costs,
resulting in a net reduction in health care costs for the ad-
herent group.19
The present study builds on these observations and ex-
tends the analysis to include the impact of compliance on
short-term disability. Gibson found that adherence to oral
hypoglycemic agents correlated with lower rates of emer-
gency room admissions and hospitalizations, and also with
fewer days of short-term disability absence.17 In a concep-
tually similar analysis, Carls used a large commercial claims
database to show that length of short-term disability was
significantly lower among those employees who were ad-
herent to their oral and injectable diabetes medications, with
2.1 fewer days of short-term disability for compliant indi-
viduals as compared to the noncompliant.21 The present
study confirms this association between compliance and
duration of short-term disability; furthermore, the current
work monetizes the differences in short-term disability costs
between the compliant and the noncompliant and empha-
sizes the impact of compliance on the incidence of short-term
disability.
Recent trends in health care costs and changes in benefit
design suggest that the potential impact of compliance on
costs may be even greater than that observed in this study.
The health care and disability cost data used in this analysis
are from 2001 to 2007. Although the rate of growth in
health care spending is not as rapid now as it was in the early
2000s, health care costs continue to climb as medical inflation
rates outpace the overall US inflation rate; indeed, there is
evidence that the slow rate of growth in health care spending
observed during the 2007–2009 recession has begun to ac-
celerate.28 The steady rise of medical, pharmacy, and dis-
ability costs since 2007 further underscores the importance of
compliance as a cost-containment strategy. Benefit plan de-
signs also have evolved since 2007, with more emphasis on
consumerism and higher deductibles for employees. In this
environment, increasing medication compliance may be
Table 2. Characteristics of the Compliant and the Noncompliant
Characteristic Compliant Noncompliant
n 2820 2158
Mean age, years (– S.D) 54.2 (– 6.4) 51.5 (– 8.4)
% Male 89.8 79.2
% Hourly job type 80.9 76.6
Mean Charlson Comorbidity score (– S.D) 2.25 (– 1.81) 1.93 (– 1.91)
Mean (paid) medical costs in Year 1 (– S.D) $4313 (– $10,782) $5192 (– $17,723)
Mean (paid) pharmacy costs in Year 1 (– S.D) $3347 (– $3546) $1727 (– $2372)
Mean (paid) pharmacy costs for hypoglycemic
agents (– S.D)
$2412 (– $2404) $785 (– $1262)
Mean health care costs for Year 1 ( – S.D) $7660 (– $11,704) $6919 (– $18,301)
Mean STD costs for Year 1 (– S.D) $985 (– $3705) $1717 (– $5360)
Mean STD duration for Year 1 (– S.D) 1.7 weeks (– 6.5) 2.7 weeks (– 8.3)
S.D., standard deviation; STD, short-term disability.
Table 3. General Linear Regression Results: Relationship Between Compliance and Costs
Characteristic Compliant Noncompliant P
Mean (paid) medical costs in Year 1 $4627 $5974 0.0008
Mean (paid) pharmacy costs in Year 1 $3155 $1668 < 0.0001
Mean (paid) pharmacy costs for hypoglycemic agents $2168 $614 < 0.0001
Mean health care costs for Year 1 $7782 $7642 0.7370
Mean STD costs for Year 1 $1161 $1840 < 0.0001
Mean STD duration for Year 1 1.9 weeks 2.8 weeks < 0.0001
Mean STD costs for Year 1, for only those with STD claims $7667 (N = 451) $9113 (N = 465) 0.0101
Mean STD duration for Year 1, for only those with STD claims 10.5 weeks 11.9 weeks 0.1207
STD, short-term disability.
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instrumental in saving money for both the employer and the
employee. A relatively new approach to employee benefits,
value-based insurance design (VBID), may help redefine the
relationship between medication compliance and health care
savings, especially given that preliminary research indicates
that VBID has a broad, positive impact on medication com-
pliance among employees with chronic conditions.29
If better medication compliance can cut employer costs
and improve employee health, then what interventions can
successfully increase patient compliance? In the words of a
recent review, the current methods of improving adherence
for long-term chronic health conditions are complex and
often ineffective.30 In general, simplifying dosing regimens
and increasing interactions between patients and health care
professionals can produce improvements in compliance, al-
though concomitant improvements in clinical outcomes are
not always observed.30,31 Interventions to improve compli-
ance with antidiabetic drug regimens were reviewed recently
by the Agency for Healthcare Research and Quality, which
found that only 1 program—care coordination and collabo-
rative care—had a beneficial impact on medication adher-
ence; all other approaches did not produce consistent
improvements in compliance and therefore were deemed
insufficient for lack of consistency or precision in the re-
sults.32 Newer approaches based on VBID33 and novel health
technologies34 offer promise, as do patient-centered medical
homes and accountable care organizations that emphasize
compliance metrics.35 However, results from these models
still must be widely validated and quantified. More research
on the psychosocial determinants of compliance and the
development of interventions targeted toward these deter-
minants also are needed.36
Limitations
This study has several limitations that should be consid-
ered when interpreting the results. Participants were identi-
fied solely on the basis of pharmacy records with no
verification of diagnosis or disease state from the corre-
sponding medical records. Given that compliance was cal-
culated based on drug refill data from pharmacy claims, the
measure of drug compliance was more accurately a measure
of drug possession. Claims information may designate when
a prescription is filled, but it cannot indicate whether the
patient actually takes the medication appropriately. Patients
may also obtain medications from other sources (such as
physician samples, self-pay opportunities, or drug sharing)
that claims records cannot capture. Even for those patients
who received and took their prescriptions as recommended,
this study could not determine if those patients were pre-
scribed the optimal therapies for their disease state or if their
conditions were managed correctly. Obviously, claims-based
methods of measuring compliance are not perfect, although
these methods are popular in the compliance and adherence
literature,37 and although previous studies have shown an
association between claims-generated measures of compli-
ance and clinical outcomes for patients with diabetes.38
Some lifestyle-associated variables—such as diet, exercise,
and self-management skills—could not be included in the
model even though their impact on diabetes progression and
associated costs could be significant. Other potentially im-
portant variables (such as race) were not available from data
sources. As mentioned previously, the study population was
not treatment- or disease-state homogenous because it con-
sisted of a mix of patients, ranging from those newly diag-
nosed with diabetes to those with advanced disease.
Although this heterogeneity does realistically mirror the
nature of diabetes in the workplace, it also may complicate
the analysis and its interpretation. Individuals taking insulin
were excluded from this study, even though a significant
percentage of diabetes patients do inject insulin to control
their disease; the most recent statistics from the Centers for
Disease Control and Prevention indicate that 12% of patients
with diabetes use insulin alone, and 14% use insulin in
combination with oral hypoglycemic agents to manage their
conditions.39 The economics of this particular segment of the
population with diabetes may warrant additional attention
because the relationships between compliance and direct/
indirect costs are even less well understood for the insulin
dependent and because almost all of those diagnosed with
diabetes will eventually require insulin to maintain good
glycemic control.40,41 Finally, this study followed individuals
with a progressive chronic disease for a relatively short
amount of time; the compliance-cost relationships discussed
in this analysis could shift if a longer follow-up time period
was used.
Conclusion
In conclusion, this study demonstrated that patients who
were compliant with their oral hypoglycemic medications
had lower mean medical costs, higher mean pharmacy
costs, lower short-term disability costs, and fewer weeks of
short-term disability absence than did the noncompliant.
These results have real-world applications because com-
pliance with oral hypoglycemic medications positively af-
fects both the employee with diabetes and the employer
who pays for that care. From the patient perspective, re-
search has shown that individuals who are compliant with
their hypoglycemic therapies have fewer complications and
lower mortality16,17 than do the noncompliant; for the em-
ployer, increased patient compliance holds promise for
helping decrease the direct and indirect costs associated
with diabetes in the workforce. In particular, better com-
pliance with hypoglycemic medications could reduce the
incidence, cost, and duration of short-term disability, an
important driver of employer health care costs. Multiple
policies and interventions designed to increase patient
compliance may produce substantial downstream benefits
to employer and employees alike, even though compliance
is a notoriously complex metric to improve. Health care
reform and the Affordable Care Act also will impact (and be
Table 4. General Linear Regression Results:
Relationship Between Compliance
and Incidence of Short-Term Disability Claims
Compliant Noncompliant
# with
disability
claim
% of compliant
population
with claim
# with
disability
claim
% of noncompliant
population
with claim
P
value
N = 451 16.0% N= 465 21.5% < 0.0001
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impacted by) these issues of compliance and costs as the
health care exchange system is implemented and any con-
comitant shifts in employer-defined benefits occur. Despite
the challenges associated with improving compliance, it is a
problem worth addressing, especially because the cost and
productivity burdens associated with diabetes will continue
to grow as the disease becomes even more prevalent in
working-aged populations.
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